



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

1st Edition

# M62

## Performance Standards for Susceptibility Testing of *Mycobacteria*, *Nocardia* spp. and Other Aerobic Actinomycetes

This document includes updated breakpoint and quality control tables for the Clinical and Laboratory Standards Institute susceptibility testing standard M24.

A CLSI supplement for global application.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

500 West Valley Road, Suite 2500

Wayne, PA 19087 USA

T: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

---

## Performance Standards for Susceptibility Testing of Mycobacteria, *Nocardia* spp., and Other Aerobic Actinomycetes

Gail L. Woods, MD  
Nancy L. Wengenack, PhD, D(ABMM)  
Grace Lin, MS  
Barbara A. Brown-Elliott, MS, MT(ASCP)SM  
Daniela Maria Cirillo, MD, PhD  
Patricia S. Conville, MS, MT(ASCP)  
Edward P. Desmond, PhD, D(ABMM)  
Scott B. Killian, BS  
Nicole M. Parrish, PhD, MHS, D(ABMM)  
Richard Pfeltz, PhD  
Elvira Richter, PhD  
John D. Turnidge, MD, BS, FRACP, FRCPA, FASM

### Abstract

Clinical and Laboratory Standards Institute document M62—*Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes* includes the minimal inhibitory concentrations and quality control ranges developed following the standards described in CLSI document M24.<sup>1</sup> The data in the tables are valid only when the methodology in CLSI document M24<sup>1</sup> is followed.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes*. CLSI supplement M62 (ISBN 978-1-68440-027-0 [Print]; ISBN 978-1-68440-028-7 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2018.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customer.service@clsi.org](mailto:customer.service@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2018 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes*. 1st ed. CLSI supplement M62. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

ISBN 978-1-68440-027-0 (Print)  
ISBN 978-1-68440-028-7 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 38, Number 22

## Committee Membership

### Document Development Committee on Antimycobacterial Susceptibility Testing

**Gail L. Woods, MD**  
**Chairholder**  
 Arkansas Children's Hospital  
 USA

Barbara A. Brown-Elliott, MS,  
 MT(ASCP)SM  
 University of Texas Health Science  
 Center at Tyler  
 USA

Beverly Metchock, DrPH,  
 D(ABMM)  
 Centers for Disease Control and  
 Prevention  
 USA

**Nancy L. Wengenack, PhD,**  
**D(ABMM)**  
**Vice-Chairholder**  
 Mayo Clinic  
 USA

Daniela Maria Cirillo, MD, PhD  
 WHO Collaborating Centre and TB  
 Supranational Reference Laboratory  
 Italy

Nicole M. Parrish, PhD, MHS,  
 D(ABMM)  
 Johns Hopkins Hospital - Pathology  
 USA

**Grace Lin, MS**  
**Committee Secretary**  
 California Department of Public  
 Health  
 USA

Patricia S. Conville, MS, MT(ASCP)  
 FDA Center for Devices and Radiological  
 Health  
 USA

Richard Pfeltz, PhD  
 BD Life Sciences  
 USA

Lynette Y. Berkeley, PhD, MT(ASCP)  
 FDA Center for Drug Evaluation and  
 Research  
 USA

Edward P. Desmond, PhD, D(ABMM)  
 California Department of Public Health  
 USA

Elvira Richter, PhD  
 Laboratory of Microbiology  
 Germany

Scott B. Killian, BS  
 Thermo Fisher Scientific  
 USA

John D. Turnidge, MD, BS, FRACP,  
 FRCPA, FASM  
 University of Adelaide  
 Australia

#### Staff

Clinical and Laboratory Standards  
 Institute  
 USA

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Kristy L. Leirer, MS  
*Editor*

Marcy L. Hackenbrack, MCM,  
 M(ASCP)  
*Project Manager*

Catherine E.M. Jenkins  
*Editor*

Laura Martin  
*Editor*

#### Acknowledgment

CLSI and the Document Development Committee on Antimycobacterial Susceptibility Testing gratefully acknowledge the following volunteers for their important contributions to the development of this document:

Joan Miquel Balada-Lluch, PharmD,  
 PhD, D(ABMM)  
 Ohio State University Wexner  
 Medical Center  
 USA

Pennan Barry, MD, MPH  
 California Department of Public Health  
 USA

Janice Washington, MT(ASCP),  
 MPH  
 FDA Center for Devices and  
 Radiological Health  
 USA

Kone Kaniga, PhD  
 Janssen Research and Development  
 USA

## Contents

Abstract.....	i
Committee Membership.....	iii
Overview of Changes.....	vii
Abbreviations and Acronyms .....	viii
Reference .....	ix
Table 1. Broth Microdilution Breakpoints and Interpretive Categories for MTBC Tested in Middlebrook 7H9 Broth Supplemented With OADC Using Commercially Available MIC Plates .....	1
Table 2. Susceptibility Testing of MTBC to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System .....	2
Table 3. Antimycobacterial Agents and Breakpoints for Testing MAC.....	4
Table 4. Antimycobacterial Agents and Breakpoints for Testing <i>M. kansasii</i> .....	5
Table 5. Antimycobacterial Agents and Breakpoints for Testing Slowly Growing Nontuberculous Mycobacteria Other Than MAC and <i>M. kansasii</i> .....	6
Table 6. Antimycobacterial Agents and Breakpoints for Testing Rapidly Growing Mycobacteria.....	7
Table 7. Antimycobacterial Agents and Breakpoints for Testing <i>Nocardia</i> spp. and Other Aerobic Actinomycetes.....	10
Table 8. Expected Antimicrobial Susceptibility Patterns of the Most Commonly Isolated <i>Nocardia</i> spp.....	12
Table 9. Expected Results for Routine and Supplemental QC Strains When Testing MTBC by a Culture-based Method.....	13
Table 10. MIC QC Ranges When Testing MTBC Using <i>M. tuberculosis</i> ATCC® 27294 (H37Rv) Tested in Middlebrook 7H9 Medium Supplemented With OADC .....	14
Table 11. QC Ranges for Susceptibility Testing of <i>M. tuberculosis</i> ATCC® 27294 (H37Rv) to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System .....	15
Table 12. Broth Microdilution QC Ranges When Testing Slowly Growing Nontuberculous Mycobacteria.....	16
Table 13. Broth Microdilution QC Ranges When Testing Rapidly Growing Mycobacteria.....	17
Table 14. Broth Microdilution QC Ranges When Testing <i>Nocardia</i> spp. and Other Aerobic Actinomycetes.....	18
The Quality Management System Approach .....	20
Related CLSI Reference Materials .....	21